4.5 Article

Predicting negative health outcomes in older general practice patients with chronic illness: Rationale and development of the PROPERmed harmonized individual participant data database

期刊

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.mad.2021.111436

关键词

Elderly; Hospitalization; Meta-analysis; Multimorbidity; Polypharmacy; Prognosis; Quality of life

资金

  1. German Innovation Fund [01VSF16018]
  2. Physician-Scientist Programme of Heidelberg University, Faculty of Medicine
  3. NIHR Oxford Biomedical Research Council (BRC)
  4. NIHR Oxford Medtech and In-Vitro Diagnostics Co-operative (MIC)
  5. NIHR Applied Research Collaboration (ARC) Oxford and Thames Valley
  6. Oxford Martin School
  7. National Institute for Health Research School for Primary Care (NIHR SPCR Launching Fellowship)

向作者/读者索取更多资源

The PROPERmed collaboration aims to derive prognostic models based on the interplay of multimorbidity and polypharmacy using an IPD database to predict patient-relevant outcomes in older patients. This helps stratify patients and enables clinicians to identify those likely to benefit most from interventions.
The prevalence of multimorbidity and polypharmacy increases significantly with age and are associated with negative health consequences. However, most current interventions to optimize medication have failed to show significant effects on patient-relevant outcomes. This may be due to ineffectiveness of interventions themselves but may also reflect other factors: insufficient sample sizes, heterogeneity of population. To address this issue, the international PROPERmed collaboration was set up to obtain/synthesize individual participant data (IPD) from five cluster-randomized trials. The trials took place in Germany and The Netherlands and aimed to optimize medication in older general practice patients with chronic illness. PROPERmed is the first database of IPD to be drawn from multiple trials in this patient population and setting. It offers the opportunity to derive prognostic models with increased statistical power for prediction of patient-relevant outcomes resulting from the interplay of multimorbidity and polypharmacy. This may help patients from this heterogeneous group to be stratified according to risk and enable clinicians to identify patients that are likely to benefit most from resource/timeintensive interventions. The aim of this manuscript is to describe the rationale behind PROPERmed collaboration, characteristics of the included studies/participants, development of the harmonized IPD database and challenges faced during this process.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据